Dixon-Vivo JV gets govt approval for smartphone manufacturing under Press Note 3

Shares of Dixon Technologies (India) Ltd ended at ₹13,490.00, up by ₹562.20, or 4.35%, on the BSE.

Shares of Dixon Technologies (India) Ltd ended at ₹13,490.00, up by ₹562.20, or 4.35%, on the BSE.

ONGC’s board has given in-principle approval to develop a 1.75 million metric tonne strategic petroleum reserve at Mangaluru, strengthening India’s emergency crude oil storage capacity.

Company’s revenue from operations increased 17.5% to ₹322 crore from ₹274 crore a year ahead. Its assets under management (AUM) crossed the ₹1 lakh crore during the quarter.

Nandish Shah of HDFC Securities said the 23,800 level remains crucial for maintaining the bullish bias. He added that the index needs to decisively cross 24,200 to improve the near-term technical outlook.

The Delhi High Court dismissed former NSE chief Chitra Ramkrishna’s challenge to provisions of the Prevention of Corruption Act, allowing proceedings against her in the alleged NSE co-location scam to move forward.

Foreign institutional investors turned net sellers after four straight sessions of buying, while domestic institutional investors extended their buying streak with over ₹2,000 crore of purchases as Indian equities rebounded from a two-day losing run.

Premier Energies has commissioned a 5.6 GW solar module manufacturing plant in Telangana, doubling its total module capacity to 11.1 GW, while also laying the foundation for a 6 GWh battery energy storage facility and an aluminium frames plant.

US stock futures traded mixed on Thursday as investors balanced easing concerns over US-Iran tensions with renewed optimism around AI and semiconductor stocks. Attention is now on SK Hynix’s upcoming Nasdaq debut, while markets continue to monitor developments in West…

The automaker reported a 32.5% jump in June vehicle sales to over 1.04 lakh units, with production rising 30% and exports crossing 5,900 units.

The recall affects only select 2 mg and 4 mg Semalix injection pens manufactured by Dr Reddy’s Laboratories, while all other semaglutide products remain unaffected.